Personalized anti-cancer therapy, maximizing immunogenicity.

Personalized anti-cancer therapy, maximizing immunogenicity.

Transforming the treatment of cancer by stimulating the immune system

Dedicated to transforming the treatment of cancer

Frame Therapeutics is dedicated to transforming the treatment of cancer by directing the immune system towards Frame neoantigens. We are developing personalized cancer immunotherapies, that are designed based on the Frame neoantigens uniquely encoded by the genome of each patient's tumor. 

Our technology is based on the combination of two recent breakthrough developments in genomics and immunotherapy. First, next generation Whole Genome sequencing technology makes it possible to rapidly identify the differences between genomes of healthy cells and tumor cells. Those mutations may lead to neoantigens and the development of a tumor. These developments make it possible to effectively create a personalized vaccine that is based on the tumor DNA sequence of the patient. The idea of vaccination is to stimulate the immune system, and to teach it to target neoantigens that it did not respond to before.

Second, new developments in immunology have made immunotherapy of cancer a new treatment option, in addition to the three classic pillars of oncological treatment: surgery, radiation and chemotherapy. Analysis of mutations across thousands of tumors helped us identify the best neoantigens to include in therapeutic vaccines that can be prepared and stored on the shelf and made available for patients and their doctors on demand.



December 15, 2020

eTheRNA immunotherapies & Frame Therapeutics collaboration is awarded with Eurostars research grant

Get in touch

At Frame Therapeutics, we are committed to progressing the field of immunotherapy, with a goal to eradicate cancer by initially developing anti-cancer vaccines that focus on the unique and individual nature of a patient’s tumor. Our dynamic team combines novel science with focus on team work, and we are looking for passionate, innovative people to join us.